MCL1 and neoplasm: It is notable that TCTP expression is commonly increased in various type of immune-refractory tumor model to T cell-mediated therapy (Figs. 2b, 4b and Supplementary Fig. 19), and targeting TCTP by using DHA in TCTPhigh tumor cells including immune-refractory tumor cells decreased immune-refractory TCTP-EGFR-MCL-1/CXCL10 signaling pathway and phenotypes (Fig. 6d–f).